NASDAQ: RYZB - RayzeBio, Inc. Common Stock

Lønnsomhet i seks måneder: 0%
Utbytte: 0.00%
Sektor: Healthcare

Kampanjeplan RayzeBio, Inc. Common Stock

Avansert tidsplan Enkel graf
Financial Markets by TradingView

Om selskapet RayzeBio, Inc. Common Stock

RayzeBio, Inc. develops radiopharmaceutical therapeutics (RPT) for the treatment of cancer. The company's lead drug candidate is RYZ101, which is in phase 3 clinical trial for the treatment of gasteroenteropancreatic neuroendocrine tumors (GEP-NETs).

flere detaljer
It also develops RYZ801, a novel proprietary peptide that targets GPC3 for delivery of Ac225 for the treatment of hepatocellular carcinoma (HCC); RYZ811, a paired diagnostic imaging agent with the peptide binder, chelator, and Ga68 as the radioisotope; and a novel proprietary small molecule that targets CA9 for delivery of Ac225 for the treatment of ccRCC. The company was incorporated in 2020 and is based in San Diego, California.
Legg til i sammenligningslisten
Legg til overvåkningsliste
Legg til portefølje
Legg til prisvarsel

IPO date 2023-09-14
ISIN US75525N1072
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://rayzebio.com
Цена ао 62.49
Prisendring per dag: 0% (62.49)
Prisendring per uke: 0% (62.49)
Prisendring per måned: 0% (62.49)
Prisendring over 3 måneder: 0% (62.49)
Prisendring over seks måneder: 0% (62.49)
Prisendring per år: 0% (62.49)
Prisendring siden begynnelsen av året: 0% (62.49)
Alle parametere

Undervurdering

Navn Betydning Karakter
P/S 0 0
P/BV 0 0
P/E 0 0
EV/EBITDA 0 0
Total: 2.5

Effektivitet

Navn Betydning Karakter
ROA, % 0 0
ROE, % 0 0
Total: 0

Utbytte

Navn Betydning Karakter
Div yield, % 0 0
DSI 0 0
Total: 0

Plikt

Navn Betydning Karakter
Debt/EBITDA 0 10
Total: 10

Vekstimpuls

Navn Betydning Karakter
Lønnsomhet Revenue, % 0 0
Lønnsomhet Ebitda, % 953.57 10
Lønnsomhet EPS, % 2126.11 10
Total: 8
Flere detaljer

Institusjoner Volum Dele, %
Viking Global Investors, L.P. 6642700 11.09
venBio Partners LLC 5158162 8.61
Versant Venture Management, LLC 5158161 8.61
VR Adviser, LLC 4030471 6.73
Wellington Management Group, LLP 3504409 5.85
Sofinnova Investments, Inc. 2419528 4.04
Orbimed Advisors LLC. 2365213 3.95
Redmile Group, LLC 1857706 3.1
Samsara BioCapital, LLC 1845948 3.08
Blackrock Inc. 1368838 2.28



Veileder Stillingstittel Betaling Fødselsår
Dr. Kenneth Song M.D. President, CEO & Director 646k 1975 (50 år)
Mr. Arvind Kush Chief Financial Officer 714.76k 1983 (42 år)
Dr. Susan Moran M.D. Chief Medical Officer 559.84k 1969 (56 år)
Mr. Aron Marc Knickerbocker Co-Founder N/A 1969 (56 år)
Mr. Jeff Woodley General Counsel N/A
Mr. Eric Bischoff Senior Vice President of Development & Operations N/A
Dr. Gary G. Li Ph.D. Senior Vice President of Biology & Translational Medicine N/A
Ms. Kimberly Ma M.S. Senior Vice President of Clinical Operations N/A
Dr. Nicholas D. Smith Ph.D. Senior Vice President of Chemistry Innovation N/A
Mr. Abhi Bhat Ph.D. Senior VP of Chemistry & Head of Discovery N/A

Adresse: United States, San Diego. CA, 5505 Morehouse Drive - åpne i Google maps, åpne Yandex-kart
Nettsted: https://rayzebio.com